Olesya Vladimirovna Paina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olesya Vladimirovna Paina has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Lyudmila Stepanovna Zubarovskaya
I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of the Russian Federation
33 shared publications - Elena Vladimirovna Semenova
The R.M. Gorbacheva Research Institute for Pediatric Oncology, Hematology and Transplantation of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation
20 shared publications - Polina Valerievna Kozhokar
The R.M. Gorbacheva Research Institute for Pediatric Oncology, Hematology and Transplantation of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation
18 shared publications - Zhemal Zarifovna Rakhmanova
The R.M. Gorbacheva Research Institute for Pediatric Oncology, Hematology and Transplantation of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation
17 shared publications - Lubov Alexandrovna Tsvetkova
Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia
13 shared publications - Tatiana Leonidovna Gindina
RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022
13 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 102-111
Results of second allogeneic hematopoietic stem cell transplantation for graft failure after first allogeneic hematopoietic stem cell transplantation complicated by the development of macrophage activation syndrome in children with high-risk acute leukemia
Introduction. Graft failure (GF) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a life-threatening complication, with an incidence of 5–20% in pediatric patients with acute leukemia. Macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (sHLH) represents one of the most aggressive triggers of GF, being closely associated with cytokine storm, multiple organ dysfunction, and high transplant-related mortality. In the setting of primary or secondary GF, a second allo-HSCT remains the only potentially curative treatment option; however, performing it against a background of hyperinflammation carries substantial risks of fatal complications and recurrent non-engraftment. The aim of the study – to evaluate factors influencing the rates of non-engraftment, overall survival, and relapse-free survival following second allo-HSCT in pediatric patients with acute leukemia who suffered primary or secondary GF after their first allo-HSCT. Materials and methods. This retrospective single-center study included 44 pediatric patients (median age 9.4 years) with acute myeloid leukemia (n = 11), acute lymphoblastic leukemia (n = 28), and myeloproliferative neoplasms (n = 5). Primary GF was diagnosed in 65.9% of patients, while secondary GF/rejection occurred in 34.1%. Key triggers of MAS/sHLH included viral infections (Epstein–Barr virus, cytomegalovirus, human herpes virus 6, parvovirus B19), bacterial/fungal complications, and cytokine release syndrome. Prior to the second HSCT, conditioning regimens consisted of reduced-intensity conditioning in 79.5% and anti-thymocyte globulin-based conditioning in 20.5%; a subset of patients received anti-cytokine therapy. A switch to a different HLA-matched donor was performed in 47.7% of cases. The median follow-up was 3 years. Results. The cumulative incidence of engraftment was 73% (median time to neutrophil recovery – 15 days). One-year overall survival was 64% (95% confidence interval (CI) 48–76), relapse-free survival was 57% (95% CI 41–70), and non-relapse mortality was 34% (95% CI 20–48). The main causes of death were infectious complications (n = 7), hepatic veno-occlusive disease/sinusoidal obstruction syndrome/transplant-associated thrombotic microangiopathy (n = 6), acute respiratory distress syndrome (n = 3), and cerebrovascular accident (n = 2). The incidence of grade II–IV acute GVHD was 61%, with grade III–IV occurring in 36%. HLA donor switch, stem cell source, and conditioning regimen, including anti-thymocyte globulin use, did not demonstrate a statistically significant impact on overall survival. Conclusion. A second allo-HSCT in pediatric patients with GF complicated by MAS/sHLH demonstrates acceptable engraftment and survival outcomes, remaining the only available option for long-term disease control. The high incidence of early immunological complications and non-relapse mortality necessitates exactly pre-transplant optimization, performing of weekly serum ferritin and inflammatory marker monitoring, and morphological confirmation of hemophagocytosis during the early post-transplant period (days +14 to +21), particularly in the absence of hematopoietic recovery. Optimization of targeted anti-cytokine therapy and intensified prophylaxis/management of infectious complications represent priority strategies to reduce transplant-related mortality.
- 19 August 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (3) , 102-111
Open AccessResults of second allogeneic hematopoietic stem cell transplantation for graft failure after first allogeneic hematopoietic stem cell transplantation complicated by the development of macrophage activation syndrome in children with high-risk acute leukemia
Introduction. Graft failure (GF) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a life-threatening complication, with an incidence of 5–20% in pediatric patients with acute leukemia. Macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (sHLH) represents one of the most aggressive triggers of GF, being closely associated with cytokine storm, multiple organ dysfunction, and high transplant-related mortality. In the setting of primary or secondary GF, a second allo-HSCT remains the only potentially curative treatment option; however, performing it against a background of hyperinflammation carries substantial risks of fatal complications and recurrent non-engraftment. The aim of the study – to evaluate factors influencing the rates of non-engraftment, overall survival, and relapse-free survival following second allo-HSCT in pediatric patients with acute leukemia who suffered primary or secondary GF after their first allo-HSCT. Materials and methods. This retrospective single-center study included 44 pediatric patients (median age 9.4 years) with acute myeloid leukemia (n = 11), acute lymphoblastic leukemia (n = 28), and myeloproliferative neoplasms (n = 5). Primary GF was diagnosed in 65.9% of patients, while secondary GF/rejection occurred in 34.1%. Key triggers of MAS/sHLH included viral infections (Epstein–Barr virus, cytomegalovirus, human herpes virus 6, parvovirus B19), bacterial/fungal complications, and cytokine release syndrome. Prior to the second HSCT, conditioning regimens consisted of reduced-intensity conditioning in 79.5% and anti-thymocyte globulin-based conditioning in 20.5%; a subset of patients received anti-cytokine therapy. A switch to a different HLA-matched donor was performed in 47.7% of cases. The median follow-up was 3 years. Results. The cumulative incidence of engraftment was 73% (median time to neutrophil recovery – 15 days). One-year overall survival was 64% (95% confidence interval (CI) 48–76), relapse-free survival was 57% (95% CI 41–70), and non-relapse mortality was 34% (95% CI 20–48). The main causes of death were infectious complications (n = 7), hepatic veno-occlusive disease/sinusoidal obstruction syndrome/transplant-associated thrombotic microangiopathy (n = 6), acute respiratory distress syndrome (n = 3), and cerebrovascular accident (n = 2). The incidence of grade II–IV acute GVHD was 61%, with grade III–IV occurring in 36%. HLA donor switch, stem cell source, and conditioning regimen, including anti-thymocyte globulin use, did not demonstrate a statistically significant impact on overall survival. Conclusion. A second allo-HSCT in pediatric patients with GF complicated by MAS/sHLH demonstrates acceptable engraftment and survival outcomes, remaining the only available option for long-term disease control. The high incidence of early immunological complications and non-relapse mortality necessitates exactly pre-transplant optimization, performing of weekly serum ferritin and inflammatory marker monitoring, and morphological confirmation of hemophagocytosis during the early post-transplant period (days +14 to +21), particularly in the absence of hematopoietic recovery. Optimization of targeted anti-cytokine therapy and intensified prophylaxis/management of infectious complications represent priority strategies to reduce transplant-related mortality.
- Open Access
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 143-151
The effect of monoclonal antibodies on herpes virus reactivation and graft failure in children in the early period after allogeneic hematopoietic stem cell transplantation
Aim: To study herpes virus reactivation in the early post-transplant period in children treated with monoclonal antibodies and subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as analyze the effect of herpes virus infections on the development of graft failure and macrophage activation syndrome (MAS). Materials and methods. The study included a total of 249 patients who had received their first allo-HSCT between January 2018 and December 2023. We studied the incidence of virus reactivation, MAS and graft failure and analyzed graft failure risk factors. Fifty-three (21%) patients were found to have not been tested for viral infections and therefore, excluded from the study. Results. Virus reactivation before Day +100 was identified in 155 (79%) patients at a median of 24 days after allo-HSCT. A total of 81 (32.5%) patients developed graft failure, with prior herpes virus reactivation registered in 66 (75%) of them. MAS was diagnosed in 33 (13.2%) cases, with 29 of these patients later developing graft failure (mostly, primary graft failure – 18 (54%) cases). Seventy-two enrolled patients received monoclonal antibodies prior to allo-HSCT. Out of these, 46 (63.8%) children developed a viral infection, and 28.9% also experienced graft failure (chiefly, primary graft failure). Conclusion. Herpes virus reactivation, MAS and treatment with monoclonal antibodies prior to allo-HSCT are risk factors for graft failure. Pre-transplant monoclonal antibody therapy is also a risk factor for herpes virus reactivation, MAS and graft failure.
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 143-151
Open AccessThe effect of monoclonal antibodies on herpes virus reactivation and graft failure in children in the early period after allogeneic hematopoietic stem cell transplantation
Aim: To study herpes virus reactivation in the early post-transplant period in children treated with monoclonal antibodies and subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) as well as analyze the effect of herpes virus infections on the development of graft failure and macrophage activation syndrome (MAS). Materials and methods. The study included a total of 249 patients who had received their first allo-HSCT between January 2018 and December 2023. We studied the incidence of virus reactivation, MAS and graft failure and analyzed graft failure risk factors. Fifty-three (21%) patients were found to have not been tested for viral infections and therefore, excluded from the study. Results. Virus reactivation before Day +100 was identified in 155 (79%) patients at a median of 24 days after allo-HSCT. A total of 81 (32.5%) patients developed graft failure, with prior herpes virus reactivation registered in 66 (75%) of them. MAS was diagnosed in 33 (13.2%) cases, with 29 of these patients later developing graft failure (mostly, primary graft failure – 18 (54%) cases). Seventy-two enrolled patients received monoclonal antibodies prior to allo-HSCT. Out of these, 46 (63.8%) children developed a viral infection, and 28.9% also experienced graft failure (chiefly, primary graft failure). Conclusion. Herpes virus reactivation, MAS and treatment with monoclonal antibodies prior to allo-HSCT are risk factors for graft failure. Pre-transplant monoclonal antibody therapy is also a risk factor for herpes virus reactivation, MAS and graft failure.
- Open Access
- 22 April 2025
- Published by Moscow State University of Psychology and Education in Counseling Psychology and Psychotherapy
- Vol. 33 (1) , 142-153
Psychological Support of Hematopoietic Stem Cell Donation with Sibling Donors: a Case Report
The article concerns our experience of psychological assistance for the sibling donors in the course of hematopoietic stem cell transplantation (HSCT) procedure. We discuss psychological support in a case of a 6-year old girl with acute myeloid leukemia and her donor, a 20-year old brother. We describe our experience of communications between clinical team, medical psychologist, patient’s family, and the potential donor. The psychological assistance resulted into lower distress level observed in the donor of hematopoietic stem cells, as well as higher satisfaction with making the decision and involvement of the whole family into the treatment process. During communications with family members, individual needs of the sibling donor should be considered, with respect to the form and extent of psychological support in the course of donorship.
- 22 April 2025
- Published by Moscow State University of Psychology and Education in Counseling Psychology and Psychotherapy
- Vol. 33 (1) , 142-153
Open AccessPsychological Support of Hematopoietic Stem Cell Donation with Sibling Donors: a Case Report
The article concerns our experience of psychological assistance for the sibling donors in the course of hematopoietic stem cell transplantation (HSCT) procedure. We discuss psychological support in a case of a 6-year old girl with acute myeloid leukemia and her donor, a 20-year old brother. We describe our experience of communications between clinical team, medical psychologist, patient’s family, and the potential donor. The psychological assistance resulted into lower distress level observed in the donor of hematopoietic stem cells, as well as higher satisfaction with making the decision and involvement of the whole family into the treatment process. During communications with family members, individual needs of the sibling donor should be considered, with respect to the form and extent of psychological support in the course of donorship.
- Open Access
- 20 January 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (4) , 35-43
Results of therapy for relapse associated with the loss HLA of heterozygosity in children with acute leukemia
Introduction. The prognosis for patients with relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains extremely unfavorable, with long-term overall survival (OS) rates less than 10 %. One of the major acquired mechanisms of immunological resistance is loss heterozygosity of HLA (LoH) genes located on chromosome 6. For patients who have developed HLA LoH relapse, immunotherapy based on independent antigen recognition pathways such as blinatumomab therapy, CAR-T therapy or second allo-HSCT is being considered.The aim of the study – to analyze the efficacy of immunotherapy options in children with HLA LoH relapse based on donor lymphocyte infusions (DLI), blinatumomab and second allo-HSCT.Materials and methods. We have analyzed 26 patients with HLA LoH confirmed relapse with bone marrow involvement after allo-HSCT. Acute myeloid leukemia was detected in 6 (23 %) patients, acute lymphoblastic leukemia (ALL) in 20 (77 %) patients (B-ALL in 16 patients, T-ALL in 4 patients). Most patients were observed after allo-HSCT from a haploidentical donor, in 24 (92 %) patients and 2 (7.6 %) patients developed relapse after allo-HSCT from a full matched related donor. Isolated medullary relapse was diagnosed in 20 patients; combined relapse was noted in 6 patients (with CNS involvement in 5 patients, testicular relapse in 1 patient).Results. In the bispecific T-cell activator immunotherapy group, 5 patients with ALL received blinatumomab. Blinatumomab in combination with DLI was given to 3 patients. A response to therapy by the clinical and hematological remission was observed in all patients. MRD negative status was achieved in 4 patients. Subsequently, 2 patients developed medullary relapse and died of the disease progression; 1 patient died of neurotoxic complications after second allo-HSCT; 2 patients are alive in remission after the second allo-HSCT, with follow-up of 10 and 4 months. Second allo-HSCT was performed in 8 patients, with donor change in 7 patients. In the comparable analysis of the efficacy of HLA LoH relapse therapy, the 2-year OS in the second allo-HSCT group was 71.4 %, compared to 26.3 % in patients who did not undergo second allo-HSCT with donor change (p = 0.06). Comparing the OS results of patients with second allo-HSCT (n = 7), DLI (n = 8) and other therapy (n = 11), the favorable effect was seen by the second allo-HSCT group, where the OS was 71.4 %, 25 % and 27.3 % respectively (p = 0.045).Conclusion. The presented analysis of the efficacy of different therapeutic options for HLA LoH relapse shows a significant benefit of the second allo-HSCT in this cohort. The investigation of loss of HLA (LoH) heterozygosity in relapse after allo-HSCT in routine practice may differentiate approaches to relapse therapy and decrease the time frame for the second allo-HSCT.
- 20 January 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (4) , 35-43
Open AccessResults of therapy for relapse associated with the loss HLA of heterozygosity in children with acute leukemia
Introduction. The prognosis for patients with relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains extremely unfavorable, with long-term overall survival (OS) rates less than 10 %. One of the major acquired mechanisms of immunological resistance is loss heterozygosity of HLA (LoH) genes located on chromosome 6. For patients who have developed HLA LoH relapse, immunotherapy based on independent antigen recognition pathways such as blinatumomab therapy, CAR-T therapy or second allo-HSCT is being considered.The aim of the study – to analyze the efficacy of immunotherapy options in children with HLA LoH relapse based on donor lymphocyte infusions (DLI), blinatumomab and second allo-HSCT.Materials and methods. We have analyzed 26 patients with HLA LoH confirmed relapse with bone marrow involvement after allo-HSCT. Acute myeloid leukemia was detected in 6 (23 %) patients, acute lymphoblastic leukemia (ALL) in 20 (77 %) patients (B-ALL in 16 patients, T-ALL in 4 patients). Most patients were observed after allo-HSCT from a haploidentical donor, in 24 (92 %) patients and 2 (7.6 %) patients developed relapse after allo-HSCT from a full matched related donor. Isolated medullary relapse was diagnosed in 20 patients; combined relapse was noted in 6 patients (with CNS involvement in 5 patients, testicular relapse in 1 patient).Results. In the bispecific T-cell activator immunotherapy group, 5 patients with ALL received blinatumomab. Blinatumomab in combination with DLI was given to 3 patients. A response to therapy by the clinical and hematological remission was observed in all patients. MRD negative status was achieved in 4 patients. Subsequently, 2 patients developed medullary relapse and died of the disease progression; 1 patient died of neurotoxic complications after second allo-HSCT; 2 patients are alive in remission after the second allo-HSCT, with follow-up of 10 and 4 months. Second allo-HSCT was performed in 8 patients, with donor change in 7 patients. In the comparable analysis of the efficacy of HLA LoH relapse therapy, the 2-year OS in the second allo-HSCT group was 71.4 %, compared to 26.3 % in patients who did not undergo second allo-HSCT with donor change (p = 0.06). Comparing the OS results of patients with second allo-HSCT (n = 7), DLI (n = 8) and other therapy (n = 11), the favorable effect was seen by the second allo-HSCT group, where the OS was 71.4 %, 25 % and 27.3 % respectively (p = 0.045).Conclusion. The presented analysis of the efficacy of different therapeutic options for HLA LoH relapse shows a significant benefit of the second allo-HSCT in this cohort. The investigation of loss of HLA (LoH) heterozygosity in relapse after allo-HSCT in routine practice may differentiate approaches to relapse therapy and decrease the time frame for the second allo-HSCT.
- Open Access
- 13 December 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (4) , 95-106
Immunoadoptive effect of donor lymphocyte infusion-induced acute graft-versus-host disease in children with acute leukemia
Donor lymphocyte infusion (DLI) for prophylactic purposes enhances the immunoadoptive antitumor effect, thereby reducing the risk of relapse after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute leukemia. One of the main limiting factors for the use of DLI is the risk of developing graft-versus-host disease (GVHD). According to studies, the incidence of this complication of DLI ranges from 15% to 45% for acute GVHD (aGVHD) and from 10% to 50% for the chronic form. The development of GVHD after DLI also leads to enhancement of the antitumor effect and reduces the risk of relapse. At the same time, an increased risk of relapse is associated with the loss of HLA heterozygosity after haploidentical HSCT, and the role of GVHD in this process has not been investigated yet. In this single-center retrospective study, we performed a comparative analysis of the risk of bone marrow and extramedullary relapses in pediatric patients with acute lymphoblastic leukemia and acute myeloid leukemia who had received prophylactic DLI after allogeneic HSCT. We also assessed the severity of DLI-induced aGVHD and the incidence and severity of chronic GVHD, and investigated the relationship between aGVHD and the loss of HLA heterozygosity. We identified two groups of patients: those who had received prophylactic DLI (an intervention group; n = 41) and those who had not (a comparison group; n = 46). Informed consent to the inclusion in the study was obtained from all the patients/legal representatives. Protocol (No. 249 dated 31.05.2021) was registered in the Ethics Committee of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation. All the patients were divided into four subgroups according the use of IDL and the development of aGVHD: +DLI – patients with DLI and without aGVHD (n = 34); +DLIGVHD – patients with DLI-induced aGVHD (n = 7); –DLI – patients without DLI and aGVHD (n = 34); –DLIGVHD – patients without DLI and with a history of aGVHD (n = 12). A total of 7 (17%) cases of DLI-induced aGVHD were recorded. There were no statistically significant differences in the incidence and severity of gastrointestinal tract involvement (p = 1) and liver involvement (p = 0.75) between the 2 groups. The incidence of grade III–IV skin GVHD (p = 0.06) was higher in the non-DLI group. No deaths associated with DLI-induced GVHD were recorded. The median number of aGVHD treatment lines (2 (1–4) and 1 (1–2); p = 0.2) and the duration of treatment (63 (23–1455) days and 70 (44–111) days; p = 0.72) were similar in the 2 groups. The incidence of chronic GVHD in the DLI group (n = 7; 17%) and in the comparison group (n = 12; 26%) did not differ significantly (p = 0.45). The cumulative incidence of bone marrow relapses was significantly lower in those patients who developed aGVHD, after DLI or without DLI (–DLI 63% (95% confidence interval (CI) 43–77), +DLI 41% (95% CI 24–57), –DLIGVHD 21% (95% CI 5–46), +DLIGVHD 14% (1–50%) (p = 0.003)). There were no significant differences between the study groups in terms of the cumulative incidence of extramedullary relapses that ranged from 16% to 29% (p = 0.8). The overall survival of the patients with aGVHD (from the –DLIGVHD and +DLIGVHD groups) was 86% (95% CI 33–98) and 84% (95% CI 50–96), respectively, and it was statistically significantly different from the overall survival of the patients without aGVHD: 54% (95% CI 35–70) and 38% (95% CI 20–56) in the +DLI and –DLI subgroups, respectively (p = 0.012). The loss of HLA heterozygosity was evaluated in 22 (40%) out of 55 patients with a post-transplant relapse. In total, HLA haplotype loss was detected in 7 (32%) patients, 3 of whom were from the +DLI group (42.9%), 2 from the –DLI group (28.6%), and another 2 from the –DLIGVHD group (28.6%). Out of 15 individuals without HLA loss, one patient (6.7%) had a history aGVHD and did not receive DLI (p = 0.57). Thus, prophylactic DLI in children with acute lymphoblastic leukemia and acute myeloid leukemia is shown to be effective in preventing bone marrow relapses after allogeneic HSCT. The development of aGVHD has a potentiating effect resulting in increased immunoadoptive activity of donor lymphocytes. The severity and clinical manifestations of DLI-induced aGVHD in pediatric patients do not differ significantly from those patients who develop classical aGVHD early after transplantation.
- 13 December 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (4) , 95-106
Open AccessImmunoadoptive effect of donor lymphocyte infusion-induced acute graft-versus-host disease in children with acute leukemia
Donor lymphocyte infusion (DLI) for prophylactic purposes enhances the immunoadoptive antitumor effect, thereby reducing the risk of relapse after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute leukemia. One of the main limiting factors for the use of DLI is the risk of developing graft-versus-host disease (GVHD). According to studies, the incidence of this complication of DLI ranges from 15% to 45% for acute GVHD (aGVHD) and from 10% to 50% for the chronic form. The development of GVHD after DLI also leads to enhancement of the antitumor effect and reduces the risk of relapse. At the same time, an increased risk of relapse is associated with the loss of HLA heterozygosity after haploidentical HSCT, and the role of GVHD in this process has not been investigated yet. In this single-center retrospective study, we performed a comparative analysis of the risk of bone marrow and extramedullary relapses in pediatric patients with acute lymphoblastic leukemia and acute myeloid leukemia who had received prophylactic DLI after allogeneic HSCT. We also assessed the severity of DLI-induced aGVHD and the incidence and severity of chronic GVHD, and investigated the relationship between aGVHD and the loss of HLA heterozygosity. We identified two groups of patients: those who had received prophylactic DLI (an intervention group; n = 41) and those who had not (a comparison group; n = 46). Informed consent to the inclusion in the study was obtained from all the patients/legal representatives. Protocol (No. 249 dated 31.05.2021) was registered in the Ethics Committee of the I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of the Russian Federation. All the patients were divided into four subgroups according the use of IDL and the development of aGVHD: +DLI – patients with DLI and without aGVHD (n = 34); +DLIGVHD – patients with DLI-induced aGVHD (n = 7); –DLI – patients without DLI and aGVHD (n = 34); –DLIGVHD – patients without DLI and with a history of aGVHD (n = 12). A total of 7 (17%) cases of DLI-induced aGVHD were recorded. There were no statistically significant differences in the incidence and severity of gastrointestinal tract involvement (p = 1) and liver involvement (p = 0.75) between the 2 groups. The incidence of grade III–IV skin GVHD (p = 0.06) was higher in the non-DLI group. No deaths associated with DLI-induced GVHD were recorded. The median number of aGVHD treatment lines (2 (1–4) and 1 (1–2); p = 0.2) and the duration of treatment (63 (23–1455) days and 70 (44–111) days; p = 0.72) were similar in the 2 groups. The incidence of chronic GVHD in the DLI group (n = 7; 17%) and in the comparison group (n = 12; 26%) did not differ significantly (p = 0.45). The cumulative incidence of bone marrow relapses was significantly lower in those patients who developed aGVHD, after DLI or without DLI (–DLI 63% (95% confidence interval (CI) 43–77), +DLI 41% (95% CI 24–57), –DLIGVHD 21% (95% CI 5–46), +DLIGVHD 14% (1–50%) (p = 0.003)). There were no significant differences between the study groups in terms of the cumulative incidence of extramedullary relapses that ranged from 16% to 29% (p = 0.8). The overall survival of the patients with aGVHD (from the –DLIGVHD and +DLIGVHD groups) was 86% (95% CI 33–98) and 84% (95% CI 50–96), respectively, and it was statistically significantly different from the overall survival of the patients without aGVHD: 54% (95% CI 35–70) and 38% (95% CI 20–56) in the +DLI and –DLI subgroups, respectively (p = 0.012). The loss of HLA heterozygosity was evaluated in 22 (40%) out of 55 patients with a post-transplant relapse. In total, HLA haplotype loss was detected in 7 (32%) patients, 3 of whom were from the +DLI group (42.9%), 2 from the –DLI group (28.6%), and another 2 from the –DLIGVHD group (28.6%). Out of 15 individuals without HLA loss, one patient (6.7%) had a history aGVHD and did not receive DLI (p = 0.57). Thus, prophylactic DLI in children with acute lymphoblastic leukemia and acute myeloid leukemia is shown to be effective in preventing bone marrow relapses after allogeneic HSCT. The development of aGVHD has a potentiating effect resulting in increased immunoadoptive activity of donor lymphocytes. The severity and clinical manifestations of DLI-induced aGVHD in pediatric patients do not differ significantly from those patients who develop classical aGVHD early after transplantation.
- Open Access
- 6 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 23-31
The role of high-dose methotrexate in T-cell acute lymphoblastic leukemia treatment: multicenter study results of ALL IC-BFM 2002 protocol
Backround. A progress in Tcell acute lymphoblastic leukemia (TALL) treatment has been achieved in recent years by use a combination of riskadopted chemoradiation therapy, based on highdose (5000 mg/m2) methotrexate. A prerequisite for successful therapy is carefully follow supportive care principles and recommendations, which include blood serum methotrexate concentration monitoring, leucovorin rescue and alkaline solutions use for the best methotrexate elimination and decrease its toxic effects.Aim. To assess the effectiveness of ALL ICFM 2002 protocol based on highdose methotrexate for Tcell acute lymphoblastic leukemia.Materials and methods. From 2003 to 2023 in retroprospective study 67 patients with primary diagnosed TALL were enrolled. Median age was 7.4 years (from 0 to 18 years). All the patients were treated according to riskadopted ALL ICFM 2002 protocol. The therapy efficacy was assessed by overall (OS), eventfree (EFS) and relapsefree survival analysis. The survival rates were calculated with statistic program SSS 21.0 by Kaplan–Meier method.Results. The use of highdose methotrexate for TALL treatment in ALL ICFM 2002 protocol secure high survival rates: 10‑year OS was 82.5 ± 3 %, EFS – 79.3 ± 3 %. Analyzing OS and EFS depending on prognostic risk group we found that standard risk patients had OS and EFS 85.4 ± 6.9 and 78.4 ± 8 %, intermediate – 85.6 ± 6.7 and 82 ± 7.3 % and highrisk – 34.6 ± 18.3 and 20.8 ± 17.1 % respectively (р 0.05).Conclusion. ALL ICFM 2002 protocol for TALL includes highdose (5000 mg/m2) methotrexate is an effective for standard and intermediate risk patients, but for TALL patients with unfavorable prognostic factors it is necessary a therapy modification by additional cytotoxic and targeted options (nelarabine and daratumumab) inclusion and widening the indications for allogeneic stem cell transplantation.
- 6 December 2024
- Published by Publishing House ABV Press in Oncohematology
- Vol. 19 (4) , 23-31
Open AccessThe role of high-dose methotrexate in T-cell acute lymphoblastic leukemia treatment: multicenter study results of ALL IC-BFM 2002 protocol
Backround. A progress in Tcell acute lymphoblastic leukemia (TALL) treatment has been achieved in recent years by use a combination of riskadopted chemoradiation therapy, based on highdose (5000 mg/m2) methotrexate. A prerequisite for successful therapy is carefully follow supportive care principles and recommendations, which include blood serum methotrexate concentration monitoring, leucovorin rescue and alkaline solutions use for the best methotrexate elimination and decrease its toxic effects.Aim. To assess the effectiveness of ALL ICFM 2002 protocol based on highdose methotrexate for Tcell acute lymphoblastic leukemia.Materials and methods. From 2003 to 2023 in retroprospective study 67 patients with primary diagnosed TALL were enrolled. Median age was 7.4 years (from 0 to 18 years). All the patients were treated according to riskadopted ALL ICFM 2002 protocol. The therapy efficacy was assessed by overall (OS), eventfree (EFS) and relapsefree survival analysis. The survival rates were calculated with statistic program SSS 21.0 by Kaplan–Meier method.Results. The use of highdose methotrexate for TALL treatment in ALL ICFM 2002 protocol secure high survival rates: 10‑year OS was 82.5 ± 3 %, EFS – 79.3 ± 3 %. Analyzing OS and EFS depending on prognostic risk group we found that standard risk patients had OS and EFS 85.4 ± 6.9 and 78.4 ± 8 %, intermediate – 85.6 ± 6.7 and 82 ± 7.3 % and highrisk – 34.6 ± 18.3 and 20.8 ± 17.1 % respectively (р 0.05).Conclusion. ALL ICFM 2002 protocol for TALL includes highdose (5000 mg/m2) methotrexate is an effective for standard and intermediate risk patients, but for TALL patients with unfavorable prognostic factors it is necessary a therapy modification by additional cytotoxic and targeted options (nelarabine and daratumumab) inclusion and widening the indications for allogeneic stem cell transplantation.
- Open Access
- 11 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 40-53
Oral nutritional supplements tolerance and compliance in pediatric oncology
Introduction. Patients treated with chemotherapy and hematopoietic stem cell transplantation (HSCT) often suffer from complications that have a negative impact on appetite and the functional ability of the digestive system, which can lead to the malnutrition – a factor of poor overall survival prognosis in hematology. Oral nutritional supplementation is one of the nutrition support (NS) types, which is currently developing by improving the taste properties and optimizing formula chemical composition, but is an underestimated NS option in clinical practice.The aim of the study – to evaluate oral nutritional supplements (ONS) tolerability and compliance in pediatric oncology patients during anticancer treatment.Materials and methods. From 2015 to 2022, in the Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia 988 cases of oral nutritional supplementation in patients from birth to 18 years old, with acute leukemia – 49.5 % (n = 489), hereditary diseases – 17.4 % (n = 172) and solid tumors – 16.9 % (n = 167) were included to a retrospective analysis. The median age was 7 (3–13) years. Male patients were in 61 % of cases (n = 603), female patients – 39 % (n = 385). In 74.2 % of cases (n = 733) allogeneic HSCT was used as a treatment option, in 22.4 % (n = 221) chemotherapy and autologous HSCT, in 3.4 % (n = 34) surgery, 11 of them as a primary tumor removal, 23 as a part of the main treatment’s complications cure. At the time of sipping initiation in 50.7 % of cases (n = 501), there was hyporexia, in 26.8 % of cases (n = 265) maldigestion, in 27.2 % (n = 269) malabsorption. In 54.6 % of cases (n = 203), a chronic graft-versus-host disease (GVHD) was observed, including the mucous membranes and gastrointestinal tract involvement. In 1.8 % of cases (n = 18), ONS was used in combination with breastfeeding, in 2.8 % (n = 28) with enteral nutrition and in 15.1 % (n = 149) with parenteral nutrition. The formula composition included standard (n = 766), semi-elemental (n = 97), balanced infant formula (n = 89) and specialized (n = 36) samples. The sipping usage in the relation of HSCT onset was preventive (n = 130), in the early period – up to D+30 (n = 212), D+31–100 (n = 182), D > +101 (n = 400).Results. Good ONS tolerability in the general cohort of patients was in 96.1 % (n = 948). Cases of poor tolerance were noted in 3.9 % of patients (n = 38). The factors that matched children with reduced sipping tolerance compared with acceptable one were: age – median 13.5 (4.0; 15.8, Q1 –Q3 ) and 7 (3.0; 12.0, Q1 –Q3 ) years, p = 0.002; presence of chronic GVHD – 91.3 % (n = 21) and 52 % (n = 181), p = 0.001; unpleasant formula taste – 42.1 % (n = 16) and 12.1 % (n = 115), p < 0.001, respectively. The effectiveness of sipping was evaluated before and after therapy based on the dynamics of body mass index (BMI) in three age groups: 14.5 (13.1; 16, Q1 –Q3 ) and 14.5 (13.4; 16.0, Q1 –Q3 ) in patients 2–8 years old, p = 0.12; 15.2 (13.7; 17.3, Q1 –Q3 ) and 14.7 (13.6 and 16.4, Q1 –Q3 ) in patients 9–12 years old, p = 0.009; 17.1 (14.6 and 19.9, Q1 –Q3 ) and 16.3 (14.3 and 18.4, Q1 –Q3 ) in patients aged 13–18 years, p = 0.0000. These results indicate that oral nutritional supplementation alone or as part of NS allow maintaining BMI within the average age standards, but only in younger patients in comparison with adolescents. In the group of patients with allogeneic HSCT (n = 731) in comparison with the general cohort of patients included in the follow-up, reduced ONS tolerance was determined somewhat more often – in 4.5 % of cases (n = 33). Chronic GVHD (91.3 %, n = 21, p = 0.001) was identified among the factors influencing the risk of developing reduced formula tolerance, while hyporexia (36.4 %, n = 12, p = 0.28), maldigestion (30.3 %, n = 10, p = 0.73) and malabsorption (42.4 %, n = 14, p = 0.1) did not have a negative effect. In 86.7 % of cases, patients characterized the sipping taste like: “I enjoy it”; and in infants, the criterion of adequate compliance was the absence of baby bottle rejection. Among the subjects who used sipping for more than one week with a pleasant taste for them (n = 810), 8.8 % (n = 79) developed formula rejection. In the group of patients with reduced compliance (n = 131) – who initially did not like the ONS taste and texture – an increase in the frequency of poor tolerability was noted from 2.6 to 12.2 % (n = 16), p < 0.001. Combined NS was also more often required: enteral nutrition 1.6 % (n = 14) and 10.7 % (n = 14), parenteral nutrition – 13.2 % (n = 113) and 27.5 % (n = 36), respectively, p < 0.001. Conclusions. Oral nutritional supplementation is an essential part of NS in pediatric oncology and hereditary diseases treatment, including the HSCT, which, on the example of patients with malfunctioned digestive system, has an appropriate tolerance and compliance.
- 11 August 2024
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 11 (2) , 40-53
Open AccessOral nutritional supplements tolerance and compliance in pediatric oncology
Introduction. Patients treated with chemotherapy and hematopoietic stem cell transplantation (HSCT) often suffer from complications that have a negative impact on appetite and the functional ability of the digestive system, which can lead to the malnutrition – a factor of poor overall survival prognosis in hematology. Oral nutritional supplementation is one of the nutrition support (NS) types, which is currently developing by improving the taste properties and optimizing formula chemical composition, but is an underestimated NS option in clinical practice.The aim of the study – to evaluate oral nutritional supplements (ONS) tolerability and compliance in pediatric oncology patients during anticancer treatment.Materials and methods. From 2015 to 2022, in the Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia 988 cases of oral nutritional supplementation in patients from birth to 18 years old, with acute leukemia – 49.5 % (n = 489), hereditary diseases – 17.4 % (n = 172) and solid tumors – 16.9 % (n = 167) were included to a retrospective analysis. The median age was 7 (3–13) years. Male patients were in 61 % of cases (n = 603), female patients – 39 % (n = 385). In 74.2 % of cases (n = 733) allogeneic HSCT was used as a treatment option, in 22.4 % (n = 221) chemotherapy and autologous HSCT, in 3.4 % (n = 34) surgery, 11 of them as a primary tumor removal, 23 as a part of the main treatment’s complications cure. At the time of sipping initiation in 50.7 % of cases (n = 501), there was hyporexia, in 26.8 % of cases (n = 265) maldigestion, in 27.2 % (n = 269) malabsorption. In 54.6 % of cases (n = 203), a chronic graft-versus-host disease (GVHD) was observed, including the mucous membranes and gastrointestinal tract involvement. In 1.8 % of cases (n = 18), ONS was used in combination with breastfeeding, in 2.8 % (n = 28) with enteral nutrition and in 15.1 % (n = 149) with parenteral nutrition. The formula composition included standard (n = 766), semi-elemental (n = 97), balanced infant formula (n = 89) and specialized (n = 36) samples. The sipping usage in the relation of HSCT onset was preventive (n = 130), in the early period – up to D+30 (n = 212), D+31–100 (n = 182), D > +101 (n = 400).Results. Good ONS tolerability in the general cohort of patients was in 96.1 % (n = 948). Cases of poor tolerance were noted in 3.9 % of patients (n = 38). The factors that matched children with reduced sipping tolerance compared with acceptable one were: age – median 13.5 (4.0; 15.8, Q1 –Q3 ) and 7 (3.0; 12.0, Q1 –Q3 ) years, p = 0.002; presence of chronic GVHD – 91.3 % (n = 21) and 52 % (n = 181), p = 0.001; unpleasant formula taste – 42.1 % (n = 16) and 12.1 % (n = 115), p < 0.001, respectively. The effectiveness of sipping was evaluated before and after therapy based on the dynamics of body mass index (BMI) in three age groups: 14.5 (13.1; 16, Q1 –Q3 ) and 14.5 (13.4; 16.0, Q1 –Q3 ) in patients 2–8 years old, p = 0.12; 15.2 (13.7; 17.3, Q1 –Q3 ) and 14.7 (13.6 and 16.4, Q1 –Q3 ) in patients 9–12 years old, p = 0.009; 17.1 (14.6 and 19.9, Q1 –Q3 ) and 16.3 (14.3 and 18.4, Q1 –Q3 ) in patients aged 13–18 years, p = 0.0000. These results indicate that oral nutritional supplementation alone or as part of NS allow maintaining BMI within the average age standards, but only in younger patients in comparison with adolescents. In the group of patients with allogeneic HSCT (n = 731) in comparison with the general cohort of patients included in the follow-up, reduced ONS tolerance was determined somewhat more often – in 4.5 % of cases (n = 33). Chronic GVHD (91.3 %, n = 21, p = 0.001) was identified among the factors influencing the risk of developing reduced formula tolerance, while hyporexia (36.4 %, n = 12, p = 0.28), maldigestion (30.3 %, n = 10, p = 0.73) and malabsorption (42.4 %, n = 14, p = 0.1) did not have a negative effect. In 86.7 % of cases, patients characterized the sipping taste like: “I enjoy it”; and in infants, the criterion of adequate compliance was the absence of baby bottle rejection. Among the subjects who used sipping for more than one week with a pleasant taste for them (n = 810), 8.8 % (n = 79) developed formula rejection. In the group of patients with reduced compliance (n = 131) – who initially did not like the ONS taste and texture – an increase in the frequency of poor tolerability was noted from 2.6 to 12.2 % (n = 16), p < 0.001. Combined NS was also more often required: enteral nutrition 1.6 % (n = 14) and 10.7 % (n = 14), parenteral nutrition – 13.2 % (n = 113) and 27.5 % (n = 36), respectively, p < 0.001. Conclusions. Oral nutritional supplementation is an essential part of NS in pediatric oncology and hereditary diseases treatment, including the HSCT, which, on the example of patients with malfunctioned digestive system, has an appropriate tolerance and compliance.
- Open Access
- 8 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 60-70
Inotuzumab ozogamicin as a bridging therapy to allogeneic hematopoietic stem cell transplantation in children with refractory/relapsed B-cell acute lymphoblastic leukemia
In children with acute lymphoblastic leukemia (ALL), relapse is still the leading cause of treatment failure occurring in 10–15% of cases. Overall survival after relapse plateaus at 50–60%, whereas event-free survival after second and third relapse is approximately 25% and 15%, respectively. The introduction of new immunotherapeutic agents such as blinatumomab (a bispecific T-cell engager), inotuzumab ozogamicin (InO; a CD22+ monoclonal antibody) and a chimeric antigen T-cell receptor targeted to CD19+ can significantly increase the effectiveness of treatment for relapsed ALL and help patients achieve remission faster and thus shorten the time to allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the toxicity of these novel agents and their impact on the results of allo-HSCT are still to be investigated. Our study included 55 patients with refractory B-cell ALL aged from 3 to 17 years (the median age was 10 years). The study was approved by the Independent Ethics Committee and the Scientific Council of the I.P. Pavlov First Saint Petersburg State Medical University. The patients were divided into two groups based on whether they received inotuzumab ozogamicin or not: InO+ group (n = 24; 43.6%) and InO– group (n = 31; 56.4%). The majority of the patients underwent haploidentical HSCT (n = 53; 96.4%); 1 (1.8%) patient received HSCT from a matched related donor, and 1 (1.8%) from a matched unrelated donor. Conditioning regimens before allo-HSCT included: myeloablative conditioning (n = 20; 36.4%), reduced toxicity myeloablative conditioning (n = 5; 9.1%), and reduced intensity conditioning (n = 30; 54.5%). Acute graft-versus-host disease prophylaxis with post-transplant cyclophosphamide was given to 49 (87.7%) recipients; 6 (12.3%) patients received seroprophylaxis. Basic combined immunosuppressive therapy consisting of a calcineurin inhibitor and an mTOR inhibitor was used in 35 (63.6%) cases, and single m-TOR inhibitor treatment was administered to 20 (36.4%) patients. In the InO+ group, 21 (87.5%) patients achieved complete remission with incomplete hematologic recovery before allo-HSCT: 5 (23.8%) patients had minimal residual disease (MRD), and 16 (76.2%) patients were MRD negative. In the InO– group, remission with incomplete hematologic recovery before allo-HSCT was achieved in 15 (48.4%) patients: 3 (9.7%) cases were MRD positive and 12 (38.7%) were MRD negative (p = 0.003). All the patients underwent allo-HSCT, regardless of response to prior therapy. Engraftment was achieved in the InO+ group in 20 (83.3%) children in a median of 22 days (D+22) and in the InO– group in 25 (80.6%) children in a median of 19 days (D+19). Relapse was observed in 11 (55%) patients in the InO+ group and in 15 (60%) patients in the InO– group at a median of 164 days and 203 days post-transplant, respectively (p = n. s.). In the InO+ group, 5 (31.25%) out of 16 patients in complete remission with incomplete hematologic recovery and negative MRD status relapsed after allo-HSCT within a median of 105 days (D+58 – D+169). In the InO–, 6 (50%) out of 12 patients in complete remission with incomplete hematologic recovery and negative MRD status relapsed within a median of 296 days (D+108 – D+929). Due to the small number of patients in the groups, a correlation and regression analysis showed a weak correlation between the use of InO before allo-HSCT and the occurrence of post-transplant relapse (Pearson's contingency coefficient was 0.178). Loss of the HLA haplotype at relapse was found in 1 (4.2%) patient from the InO+ group and in 2 (6.5%) patients from the InO– group (p = n. s.). Transplant-associated thrombotic microangiopathy was diagnosed in 6 (25%) recipients in the InO+ group and in 3 (9.7%) recipients in the InO– group. Eight (32%) patients in the InO+ group and 3 (9.7%) patients in the InO– group had clinical manifestations of sinusoidal obstruction syndrome. Our study suggests the effectiveness of inotuzumab ozogamicin for the treatment of relapsed B-ALL in children before allo-HSCT. Patients with large tumor burden and high expression of CD22+ would benefit the most from therapy with InO. The application of reduced intensity conditioning regimen after CD22+ directed monoclonal antibody therapy significantly improves the overall survival rates by reducing early transplant-related mortality and makes it possible to use adoptive immunotherapy as a next line of treatment. Current allo-HSCT protocols and approaches to acute graft-versus-host disease prevention help control the development of severe complications in the early post-transplant period. Our study showed that adoptive immunotherapy via donor lymphocyte infusions can be applied in patients treated with InO who experience loss of the HLA haplotype at relapse after allo-HSCT.
- 8 July 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (2) , 60-70
Open AccessInotuzumab ozogamicin as a bridging therapy to allogeneic hematopoietic stem cell transplantation in children with refractory/relapsed B-cell acute lymphoblastic leukemia
In children with acute lymphoblastic leukemia (ALL), relapse is still the leading cause of treatment failure occurring in 10–15% of cases. Overall survival after relapse plateaus at 50–60%, whereas event-free survival after second and third relapse is approximately 25% and 15%, respectively. The introduction of new immunotherapeutic agents such as blinatumomab (a bispecific T-cell engager), inotuzumab ozogamicin (InO; a CD22+ monoclonal antibody) and a chimeric antigen T-cell receptor targeted to CD19+ can significantly increase the effectiveness of treatment for relapsed ALL and help patients achieve remission faster and thus shorten the time to allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the toxicity of these novel agents and their impact on the results of allo-HSCT are still to be investigated. Our study included 55 patients with refractory B-cell ALL aged from 3 to 17 years (the median age was 10 years). The study was approved by the Independent Ethics Committee and the Scientific Council of the I.P. Pavlov First Saint Petersburg State Medical University. The patients were divided into two groups based on whether they received inotuzumab ozogamicin or not: InO+ group (n = 24; 43.6%) and InO– group (n = 31; 56.4%). The majority of the patients underwent haploidentical HSCT (n = 53; 96.4%); 1 (1.8%) patient received HSCT from a matched related donor, and 1 (1.8%) from a matched unrelated donor. Conditioning regimens before allo-HSCT included: myeloablative conditioning (n = 20; 36.4%), reduced toxicity myeloablative conditioning (n = 5; 9.1%), and reduced intensity conditioning (n = 30; 54.5%). Acute graft-versus-host disease prophylaxis with post-transplant cyclophosphamide was given to 49 (87.7%) recipients; 6 (12.3%) patients received seroprophylaxis. Basic combined immunosuppressive therapy consisting of a calcineurin inhibitor and an mTOR inhibitor was used in 35 (63.6%) cases, and single m-TOR inhibitor treatment was administered to 20 (36.4%) patients. In the InO+ group, 21 (87.5%) patients achieved complete remission with incomplete hematologic recovery before allo-HSCT: 5 (23.8%) patients had minimal residual disease (MRD), and 16 (76.2%) patients were MRD negative. In the InO– group, remission with incomplete hematologic recovery before allo-HSCT was achieved in 15 (48.4%) patients: 3 (9.7%) cases were MRD positive and 12 (38.7%) were MRD negative (p = 0.003). All the patients underwent allo-HSCT, regardless of response to prior therapy. Engraftment was achieved in the InO+ group in 20 (83.3%) children in a median of 22 days (D+22) and in the InO– group in 25 (80.6%) children in a median of 19 days (D+19). Relapse was observed in 11 (55%) patients in the InO+ group and in 15 (60%) patients in the InO– group at a median of 164 days and 203 days post-transplant, respectively (p = n. s.). In the InO+ group, 5 (31.25%) out of 16 patients in complete remission with incomplete hematologic recovery and negative MRD status relapsed after allo-HSCT within a median of 105 days (D+58 – D+169). In the InO–, 6 (50%) out of 12 patients in complete remission with incomplete hematologic recovery and negative MRD status relapsed within a median of 296 days (D+108 – D+929). Due to the small number of patients in the groups, a correlation and regression analysis showed a weak correlation between the use of InO before allo-HSCT and the occurrence of post-transplant relapse (Pearson's contingency coefficient was 0.178). Loss of the HLA haplotype at relapse was found in 1 (4.2%) patient from the InO+ group and in 2 (6.5%) patients from the InO– group (p = n. s.). Transplant-associated thrombotic microangiopathy was diagnosed in 6 (25%) recipients in the InO+ group and in 3 (9.7%) recipients in the InO– group. Eight (32%) patients in the InO+ group and 3 (9.7%) patients in the InO– group had clinical manifestations of sinusoidal obstruction syndrome. Our study suggests the effectiveness of inotuzumab ozogamicin for the treatment of relapsed B-ALL in children before allo-HSCT. Patients with large tumor burden and high expression of CD22+ would benefit the most from therapy with InO. The application of reduced intensity conditioning regimen after CD22+ directed monoclonal antibody therapy significantly improves the overall survival rates by reducing early transplant-related mortality and makes it possible to use adoptive immunotherapy as a next line of treatment. Current allo-HSCT protocols and approaches to acute graft-versus-host disease prevention help control the development of severe complications in the early post-transplant period. Our study showed that adoptive immunotherapy via donor lymphocyte infusions can be applied in patients treated with InO who experience loss of the HLA haplotype at relapse after allo-HSCT.
- 3 November 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15181
Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia
Introduction: The data on post‐transplant cyclophosphamide (PTCy) in pediatric acute leukemia after matched allo‐HSCT are limited to case series. The present study aimed to assess the results of PTCy‐based GVHD prophylaxis in a large cohort of children with acute leukemia after matched allo‐HSCT.Methods: A retrospective analysis of 190 pediatric patients with acute leukemia who had a first allograft between 2008 and 2020 from a matched sibling donor (MSD) or matched unrelated donor (MUD) was carried out. In the MSD setting, GVHD prophylaxis consisted of PTCy alone (n = 28) for the study group, and calcineurin inhibitor (CNI) ± antimetabolite (n = 30) for the control group. In MUD setting, most patients in the study group received GVHD prophylaxis with PTCy+CNI+mycophenolate mofetil (n = 42, 66.7%) or PTCy+CNI+sirolimus (n = 12, 19%). All patients (n = 69) in the control group received ATG+CNI+antimetabolite.Results: After MUD allo‐HSCT, the incidences of acute GVHD grade III‐IV and moderate/severe chronic GVHD were significantly lower in the PTCy group compared to control (6.6% vs. 35.0% and 12.7% vs. 47.1%, respectively, p < .0001). Five‐year GVHD‐free, relapse‐free survival (GRFS) after MUD allo‐HSCT was higher in the PTCy group compared to control (35.1% vs. 7.3%, p < .0001). At the same time, there was no significant difference between both groups after MSD allo‐HSCT.Conclusions: In pediatric acute leukemia, PTCy‐based GVHD prophylaxis for MUD allo‐HSCT is a feasible and effective option that results in a low incidence of GVHD. Compared to the ATG‐based approach, PTCy provides better control of GVHD in children. In pediatric allo‐HSCT from MSD, PTCy demonstrates comparable effectiveness to conventional GVHD prophylaxis.
- 3 November 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15181
Post‐transplant сyclophosphamide after matched donor hematopoietic stem cell transplantation in children with acute leukemia
Introduction: The data on post‐transplant cyclophosphamide (PTCy) in pediatric acute leukemia after matched allo‐HSCT are limited to case series. The present study aimed to assess the results of PTCy‐based GVHD prophylaxis in a large cohort of children with acute leukemia after matched allo‐HSCT.Methods: A retrospective analysis of 190 pediatric patients with acute leukemia who had a first allograft between 2008 and 2020 from a matched sibling donor (MSD) or matched unrelated donor (MUD) was carried out. In the MSD setting, GVHD prophylaxis consisted of PTCy alone (n = 28) for the study group, and calcineurin inhibitor (CNI) ± antimetabolite (n = 30) for the control group. In MUD setting, most patients in the study group received GVHD prophylaxis with PTCy+CNI+mycophenolate mofetil (n = 42, 66.7%) or PTCy+CNI+sirolimus (n = 12, 19%). All patients (n = 69) in the control group received ATG+CNI+antimetabolite.Results: After MUD allo‐HSCT, the incidences of acute GVHD grade III‐IV and moderate/severe chronic GVHD were significantly lower in the PTCy group compared to control (6.6% vs. 35.0% and 12.7% vs. 47.1%, respectively, p < .0001). Five‐year GVHD‐free, relapse‐free survival (GRFS) after MUD allo‐HSCT was higher in the PTCy group compared to control (35.1% vs. 7.3%, p < .0001). At the same time, there was no significant difference between both groups after MSD allo‐HSCT.Conclusions: In pediatric acute leukemia, PTCy‐based GVHD prophylaxis for MUD allo‐HSCT is a feasible and effective option that results in a low incidence of GVHD. Compared to the ATG‐based approach, PTCy provides better control of GVHD in children. In pediatric allo‐HSCT from MSD, PTCy demonstrates comparable effectiveness to conventional GVHD prophylaxis.
- Open Access
- 1 November 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (4) , 231-245
Clinical efficacy and safety of parenteral nutrition in hematopoietic stem cell transplantation: results of a single-center randomized controlled study
BACKGROUND: Hematopoietic stem cell transplantation frequently necessitates nutritional support. However, the safety and tolerance of parenteral nutrition have not been adequately examined, except for its association with infectious complications. AIM: To evaluate the impact of parenteral nutrition on nutritional status and its correlation with complications during the early period following hematopoietic stem cell transplantation. MATERIALS AND METHODS: From 2019–2020, 125 recipients of autologous (n=38) and allogeneic (n=87) hematopoietic stem cell transplantation were included in the study with a median age of 20 years (2–65). The chosen cohort included patients with leukemia (n=67), solid tumors (n=32), dysplasia (n=15) and lymphoproliferation (n=11). The control group (n=55) was composed of patients who did not depend on nutritional support. Parenteral nutrition was administered to the primary group (n=70) using second-generation (n=22) and third-generation (n=24) fat emulsions. In the event of contraindications, parenteral nutrition was administered without fat emulsions (n=24). To mitigate the risk of side effects, the initial dose of parenteral nutrition was 50%, with the achievement of the complete dose by the third day of therapy. RESULTS: In 95.7% of cases, mucositis was the indication for parenteral nutrition. The duration of parenteral nutrition was 2–31 days (median, 11 days). In 58.6% of cases, parenteral nutrition was initiated against the background of nausea and vomiting. During the escalation of the parenteral nutrition dose, increased nausea was observed in 7.1% of patients. Side effects were noted in 22.9% of cases: hyperglycemia (n=7), vomiting (n=6) and hypertriglyceridemia (n=3). Four patients developed complications associated with parenteral nutrition, and nutritional therapy was discontinued in 20% of cases (n=14). After hematopoietic stem cell transplantation, the primary clinical efficacy criterion, body mass index, was observed to decline in each observation group. However, it recovered by day 28 and did not differ between the comparison groups as follows: the control group — from 22.7±6.4 to 21.7±6.1 kg/m2, (p=0.42); group “2 in 1” — from 23.4±6.1 to 21.6±4 kg/m2, (p=0.56); group provided with parenteral nutrition employing second-generation fat emulsions — from 18,8±4,9 to 18.7±4.4 kg/m2, (p=0.72); group administered parenteral nutrition with third-generation fat emulsions — from 18.6±4.2 to 18.3±3.5 kg/m2, (p=0.84). The febrile neutropenia rate was 75.2% and did not vary in the control and comparison groups (p=0.54). The incidence of sepsis was 24.8% and was not influenced by the use of parenteral nutrition (p=0.07). Furthermore, sepsis risk was higher when administering parenteral nutrition “2 in 1” compared to fat emulsions-containing parenteral nutrition (p=0.002). The overall frequency of acute graft versus host disease was 16.1% and was similar in the comparison groups (p=0.65). CONCLUSION: In the cohort of patients treated with hematopoietic stem cell transplantation, parenteral nutrition regimens supplemented with second- and third-generation fat emulsions with a stepwise dose increase varied in acceptable tolerance, infection-related complications, and immunological safety, as well as effectively maintained nutritional status parameters.
- 1 November 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (4) , 231-245
Open AccessClinical efficacy and safety of parenteral nutrition in hematopoietic stem cell transplantation: results of a single-center randomized controlled study
BACKGROUND: Hematopoietic stem cell transplantation frequently necessitates nutritional support. However, the safety and tolerance of parenteral nutrition have not been adequately examined, except for its association with infectious complications. AIM: To evaluate the impact of parenteral nutrition on nutritional status and its correlation with complications during the early period following hematopoietic stem cell transplantation. MATERIALS AND METHODS: From 2019–2020, 125 recipients of autologous (n=38) and allogeneic (n=87) hematopoietic stem cell transplantation were included in the study with a median age of 20 years (2–65). The chosen cohort included patients with leukemia (n=67), solid tumors (n=32), dysplasia (n=15) and lymphoproliferation (n=11). The control group (n=55) was composed of patients who did not depend on nutritional support. Parenteral nutrition was administered to the primary group (n=70) using second-generation (n=22) and third-generation (n=24) fat emulsions. In the event of contraindications, parenteral nutrition was administered without fat emulsions (n=24). To mitigate the risk of side effects, the initial dose of parenteral nutrition was 50%, with the achievement of the complete dose by the third day of therapy. RESULTS: In 95.7% of cases, mucositis was the indication for parenteral nutrition. The duration of parenteral nutrition was 2–31 days (median, 11 days). In 58.6% of cases, parenteral nutrition was initiated against the background of nausea and vomiting. During the escalation of the parenteral nutrition dose, increased nausea was observed in 7.1% of patients. Side effects were noted in 22.9% of cases: hyperglycemia (n=7), vomiting (n=6) and hypertriglyceridemia (n=3). Four patients developed complications associated with parenteral nutrition, and nutritional therapy was discontinued in 20% of cases (n=14). After hematopoietic stem cell transplantation, the primary clinical efficacy criterion, body mass index, was observed to decline in each observation group. However, it recovered by day 28 and did not differ between the comparison groups as follows: the control group — from 22.7±6.4 to 21.7±6.1 kg/m2, (p=0.42); group “2 in 1” — from 23.4±6.1 to 21.6±4 kg/m2, (p=0.56); group provided with parenteral nutrition employing second-generation fat emulsions — from 18,8±4,9 to 18.7±4.4 kg/m2, (p=0.72); group administered parenteral nutrition with third-generation fat emulsions — from 18.6±4.2 to 18.3±3.5 kg/m2, (p=0.84). The febrile neutropenia rate was 75.2% and did not vary in the control and comparison groups (p=0.54). The incidence of sepsis was 24.8% and was not influenced by the use of parenteral nutrition (p=0.07). Furthermore, sepsis risk was higher when administering parenteral nutrition “2 in 1” compared to fat emulsions-containing parenteral nutrition (p=0.002). The overall frequency of acute graft versus host disease was 16.1% and was similar in the comparison groups (p=0.65). CONCLUSION: In the cohort of patients treated with hematopoietic stem cell transplantation, parenteral nutrition regimens supplemented with second- and third-generation fat emulsions with a stepwise dose increase varied in acceptable tolerance, infection-related complications, and immunological safety, as well as effectively maintained nutritional status parameters.